Pre-Clinical Drug Candidates

LTA4 Hydrolase Inhibitors

VIA has an exclusive option to acquire a worldwide license to proprietary leukotriene A4 (LTA4) hydrolase inhibitors. During the exclusive option period, VIA is conducting pre-clinical studies to evaluate the compounds for cardiovascular therapeutic applications.

PDE4 inhibitors

In January 2007, the Company expanded its product pipeline with the acquisition of certain patent applications, know-how and related assets (including, compounds and quantities of physical materials and reagents) related to a library of over 2,000 phosphodiesterase (“PDE”) inhibitor small molecule compounds (the “Neuro3D Compounds”) from Neuro3D, S.A., a French corporation (“Neuro3D”). The Company believes that inhibitors of certain classes of PDEs, in particular PDE4, may be novel compounds for the treatment of inflammation related to atherosclerosis. The Company has initiated pre-clinical testing of certain Neuro3D Compounds using standard industry parameters, such as target specificity, animal safety and bioavailability. The Company anticipates making a determination as to whether to initiate clinical activities with any of the Neuro3D Compounds in 2008.